Velcera Announces FDA Confirms VEL504 Clinical Program

Published: Jun 30, 2008

YARDLEY, PA--(Marketwire - June 30, 2008) - Velcera, Inc. (OTCBB: VLCR), a specialty pharmaceutical company focused on pet health, announced today the results of a pre submission conference held with the U.S. Food and Drug Administration's Center for Veterinary Medicine ("CVM") concerning Velcera's novel canine pain management product, VEL504. The meeting was held to review progress on target animal safety and efficacy studies conducted to date, and to confirm CVM's acceptance of the agreed upon plan of development. CVM confirmed the concurred protocol for the U.S. clinical field study is acceptable.

Back to news